Peter Larsson
Peter Larsson
Verified email at
Cited by
Cited by
Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens
P Larsson, H Engqvist, J Biermann, E Werner Rönnerman, ...
Scientific reports 10 (1), 1-12, 2020
Integrative genomics approach identifies molecular features associated with early-stage ovarian carcinoma histotypes
H Engqvist, TZ Parris, J Biermann, EW Rönnerman, P Larsson, ...
Scientific Reports 10 (1), 1-13, 2020
Pan-cancer analysis identifies BIRC5 as a prognostic biomarker
A Fäldt Beding, P Larsson, K Helou, Z Einbeigi, TZ Parris
BMC cancer 22 (1), 1-13, 2022
Pan-cancer analysis of genomic and transcriptomic data reveals the prognostic relevance of human proteasome genes in different cancer types
P Larsson, D Pettersson, H Engqvist, E Werner Rönnerman, ...
BMC cancer 22 (1), 993, 2022
Abstract P2-06-19: The effect of UBE2C expression on intrinsic chemosensitivity in breast cancer cell lines
TZ Parris, P Larsson, J Biermann, H Engqvist, E Werner-Rönnerman, ...
Cancer Research 79 (4_Supplement), P2-06-19-P2-06-19, 2019
The system can't perform the operation now. Try again later.
Articles 1–5